King Pharma Say Late Stage Study Of Abuse-deterrent Painkiller Remoxy Meets Primary Goal

RTTNews"12/6/2007 11:49:08 AM Thursday, Pain Therapeutics, Inc. (PTIE), a biopharmaceutical company, and King Pharmaceuticals, Inc. (KG), a vertically integrated pharmaceutical company, announced that the late stage study of chronic pain treatment candidate Remoxy has met the primary endpoint. Remoxy, an investigational drug, is an abuse-deterrent version of long-acting oxycodone, a powerful painkiller available only by prescription. The companies anticipate Remoxy to meet the needs of physicians or pharmacists who appropriately prescribe long-acting oxycodone and who try to minimize the risks of abuse, misuse or diversion."